The effect of statins on the development of new-onset type 2 diabetes: A meta-analysis of randomized controlled trials

Current Medical Research and Opinion

Volumn 24, Issue 5, 2008, Pages 1359-1362

  Coleman, Craig I ^a,b   Reinhart, Kurt ^a,b   Kluger, Jeffrey ^b   White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Hydroxymethylglutaryl coenzyme A reductase inhibitors; Meta analysis; Prevention statin; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ATTRIBUTABLE RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZATION; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

AGE DISTRIBUTION; AGE OF ONSET; AGED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 44349095752     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X292029     Document Type: Article

References (13)

1. White CM. Pharmacologic effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999;39:111-8
2. Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation 2001;103:346-7
3. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a prospective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62
4. Shepard J, Cobbe S, Ford I, et al. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333;1301-7
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
7. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713-21
8. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149-58
9. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. New Engl J Med 2007;357:10.1056/NEJMoa0706201
10. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(Suppl 1): s4-s41
11. Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261-6
12. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:1-8
13. Mann DM, Allegrante JP, Natarajan S, et al. Dietary indiscretion and statin use. Mayo Clin Proc 2007;82:951-3